Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1323-1328

  Del Papa, Nicoletta ^a   Cortiana, Michela ^b   Vitali, Claudio ^c   Silvestris, Ilaria ^b   Maglione, Wanda ^a   Comina, Denise P ^a   Lucchi, Tiziano ^d   Cortelezzi, Agostino ^d  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Villamarina Hospital   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Endothelial activation; Endothelial progenitors; Simvastatin; Systemic sclerosis; Vasculogenesis

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS; TISSUE REPAIR; ULCER;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SIMVASTATIN; STEM CELLS;

EID: 47349091867     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996;22:675-94.
2. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-10.
3. Del Papa N, Quirici N, Soligo D, et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006;54:2605-15.
4. Del Papa N, Colombo G, Fracchiolla N, et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthrtis Rheum 2004;50:1296-304.
5. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-7.
6. Vasa M, Fichtischerer S, Adler K, Mildner-Rihm C, Aicher A, Martin H. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90.
7. Walter DH, Ritting K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-24.
8. Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006;54:1946-51.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
10. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
11. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical and serological features and survival in 1,012 Italian patients. Medicine Baltimore 2002;81:139-53.
12. Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1996:51-79.
13. Inoue T. Statin therapy for vascular failure. Cardiovasc Drugs Ther 2007;21:281-95.
14. Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 2005;67:1672-6.
15. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coronary Artery Dis 2004;15:235-42.
16. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-9.
17. Wolfrum S, Grimm M, Heidbreder M, et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 2003;41:649-56.
18. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998;97:1129-35.
19. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 2003;14:599-603.
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
21. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemo-attractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002;22:1194-9.
22. Rezaie-Majd A, Prager GW, Bucek RA, Schernthaner GH, Maca T, Kress HG. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2003;23:397-403.
23. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, Naruszewicz M. Simvastatin modulates TNF-a-induced adhesion molecules expression in human endothelial cells. Life Sci 2004;75:1287-302.
24. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med 2000;6:1399-402.
25. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-76.
26. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231-6.
27. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000;6:389-95.
28. Lievadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001;108:399-405.
29. Vasa M, Fichtischerer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-90.
30. Walter DH, Schachinger V, Eisner M, Mach S. Auch-Schwelk W, Zeiher AM. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000;85:962-8.
31. Khan SS, Solomon MA, McCoy JP Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B Clin Cytom 2005;64:1-8.
32. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nature Protocol 2007;2:805-10.
33. Grisar J, Aletaha D, Steiner CW, et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 2007;66:1284-8.
34. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl J Med 2003;348:593-60.